Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient

Sponsor
Spanish Lung Cancer Group
Study ID
NCT03132493
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab 10 MG/ML — DRUG
    nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression

Study Details

The investigators will be retrospectively review the case note of patients registered in the EAP of Nivolumab. A standard anonymous data collection form will be used to collect data and to analyze it. Patients with advanced Non-Small Cell Lung Cancer previously treated and included in the SPANISH expanded access programme of nivolumab.

Key Dates

Start date
Jun 1, 2017
Status verified
Nov 2018
Primary completion
Dec 1, 2017
Completion
Sep 15, 2018

Study Design

Enrollment
676 participants (actual)

Primary Outcome Measure

Progression Free survival [ Time Frame: At 12 months ]

Related Studies